Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Oncocyte Corp
since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Oncocyte Corp since year 2005.
Table 2 shows the detailed insider transactions of Oncocyte Corp since 2005.
The reporting company's ticker symbol is OCX. The reporting company's CIK number is 1642380.
The total value of stock buying since 2005 is $5,000,000.
The total value of stock sales since 2005 is $0.
The total value of stock option exercises since 2005 is $0.
|Trading Period||Insider Buying||Insider Sales||Option Exercises|
|Trade Date||Insider Name||Trade Type||Shares||Price ($)||Value ($)|
|2018-07-26||Hesterberg Lyndal K. (Sr VP, Research & Development)||Buy||874||.00||0|
|2018-07-26||Annett William (President and CEO)||Buy||3,500||.00||0|
|2018-07-26||Last Andrew J.||Buy||6,993||.00||0|
|2018-07-26||Redmond Cavan M.||Buy||52,447||.00||0|
|2018-07-26||Levine Mitchell S (Chief Financial Officer)||Buy||3,495||.00||0|
|2018-07-26||Andrews Ronald Asbury||Buy||17,482||.00||0|
|2018-03-28||Bradsher Neal C||Buy||3,968,254||1.26||5,000,000|
Insider trading activities including stock purchases, stock sales, and option exercises of OCX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Oncocyte Corp (symbol OCX, CIK number 1642380) see the Securities and Exchange Commission (SEC) website.